MarketPulse

infectious disease

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Bavarian Nordic's Chikungunya Vaccine Wins Swiss Approval, Expanding Global Market Access

Bavarian Nordic's chikungunya vaccine VIMKUNYA wins Swiss regulatory approval, marking the fourth major authorization in 2025 following FDA, EMA, and MHRA clearances.
BVNRYregulatory approvalinfectious disease
The Motley FoolThe Motley Fool··Cory Renauer

Vir Biotech CEO Offloads $664K in Shares Amid Positive Clinical Pipeline

Vir Biotechnology CEO Marianne De Backer sold 72,559 shares worth $664,350, representing 6.76% of holdings. Sale aligns with historical patterns amid company's positive momentum.
VIRALPMYbiotechclinical trial results
GlobeNewswire Inc.GlobeNewswire Inc.··Actg

Tecovirimat Shows No Clinical Benefit Over Placebo in Mpox Trial

Tecovirimat showed no clinical benefit over placebo in treating mpox, with 79% vs 81% achieving resolution by day 29 in a major trial.
SIGAclinical trialtecovirimat